News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 25, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
May 5, 2022
Initial seribantumab clinical data from Phase 2 CRESTONE study selected for oral presentation at ASCO 2022 David Dornan, PhD appointed Chief Scientific Officer, bringing deep oncology R&D and drug...
-
Apr 27, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Mar 14, 2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...
-
Mar 3, 2022- On track to present initial clinical data from Cohort 1 of the Phase 2 CRESTONE study in mid-2022
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...